Generic drug maker Lannett Company has announced the beginning of a clinical trial of its proposed biosimilar insulin glargine referencing Lantus.
Generic drug maker Lannett Company has announced the beginning of a clinical trial of its proposed biosimilar insulin glargine referencing Lantus.
The single-center, single-dose, double-blind, randomized, 2-period crossover study in healthy volunteers is designed to compare the pharmacokinetics and pharmacodynamics of the biosimilar to the US-approved insulin glargine. The trial is being conducted in South Africa.
"Initiating a first-in-human clinical trial of our partnered insulin glargine product is a major milestone in the progression of this project," said Tim Crew, chief executive officer of Lannett, in a statement announcing the start of the trial. "We look forward to the clinical advancement of the product as an affordable treatment option, especially with 29 million Americans suffering with type 1 or type 2 diabetes."
Lannett says that the trial is intended to support the submission of an eventual Biologics License Application for the product.
News that Lannett is poised to submit a BLA for its insulin is a notable step as the United States moves toward its 2020 date for transitioning insulins to regulation as biologics.
The Biologics Price Competition and Innovation Act stipulated that a marketing application for a biologic that could have been submitted under section 505 of the Food, Drug and Cosmetic (FD&C) Act must be submitted under section 351 of the Public Health Service (PHS) Act, but some products, like insulin, were allowed a 10-year transition period, which will expire on March 23, 2020.
Starting on that date, approved applications for biologics approved under the FD&C Act will be deemed to be licensed under the PHS Act, and follow-on drugs such as insulin will have to be submitted to the FDA for regulatory review under the biosimilar approval pathway.
Once insulins are regulated as biologics, it will be possible for drug makers to seek interchangeable designations for their products.
Other drug makers seeking a piece of the United States market for insulin glargine include Mylan and Biocon, which received a Complete Response Letter for their product in June 2018. Boehringer Ingelheim and Eli Lilly’s Basaglar, which is both approved and launched in the United States, has captured 34% of the Medicaid market for long-acting insulins and saved Medicaid more than $70 million, according to a recent research letter in JAMA.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.